Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
... own development
activities within metabolic disorders and infectious diseases, it has been
decided to divest the activities within the development of spc2996
CLL. This process is ongoing.
In February 2009 Santaris Pharma's collaboration partner Enzon